Establishment Labs (NASDAQ:ESTA) Price Target Raised to $100.00 at Mizuho

Establishment Labs (NASDAQ:ESTA) had its price target raised by research analysts at Mizuho from $90.00 to $100.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price target indicates a potential upside of 24.96% from the company’s current price.

Other analysts also recently issued research reports about the stock. Needham & Company LLC lifted their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. lifted their price objective on Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research note on Wednesday, December 17th. Citigroup increased their target price on Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, December 11th. Canaccord Genuity Group raised their target price on Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Finally, BTIG Research boosted their price target on shares of Establishment Labs from $86.00 to $88.00 and gave the stock a “buy” rating in a research note on Tuesday. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $86.29.

Establishment Labs Trading Up 0.4%

ESTA traded up $0.36 on Wednesday, hitting $80.03. The company had a trading volume of 421,073 shares, compared to its average volume of 512,654. The company’s fifty day moving average price is $70.99 and its 200 day moving average price is $57.73. Establishment Labs has a 1 year low of $26.56 and a 1 year high of $83.31. The company has a current ratio of 3.33, a quick ratio of 2.10 and a debt-to-equity ratio of 15.06. The firm has a market cap of $2.33 billion, a P/E ratio of -28.18 and a beta of 0.99.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. The business had revenue of $64.62 million during the quarter, compared to analysts’ expectations of $63.80 million. Establishment Labs had a negative net margin of 43.45% and a negative return on equity of 235.45%. The business’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same period last year, the business earned ($1.19) earnings per share. As a group, equities analysts expect that Establishment Labs will post -2.41 earnings per share for the current year.

Institutional Investors Weigh In On Establishment Labs

Hedge funds have recently bought and sold shares of the stock. MV Capital Management Inc. acquired a new position in shares of Establishment Labs during the fourth quarter worth about $146,000. ADAR1 Capital Management LLC lifted its stake in Establishment Labs by 89.0% in the fourth quarter. ADAR1 Capital Management LLC now owns 171,422 shares of the company’s stock worth $12,493,000 after acquiring an additional 80,734 shares during the last quarter. Voloridge Investment Management LLC purchased a new position in Establishment Labs in the fourth quarter worth approximately $3,421,000. SummitTX Capital L.P. acquired a new position in Establishment Labs during the 4th quarter worth approximately $2,519,000. Finally, Tudor Investment Corp ET AL purchased a new stake in shares of Establishment Labs in the 4th quarter valued at approximately $12,852,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

Key Headlines Impacting Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Q4 results beat estimates: ESTA reported a loss of $0.09/share versus consensus -$0.22 and revenue of $64.62M (up ~45% YoY), showing much narrower losses and stronger top-line momentum. Press Release
• Positive Sentiment: FY-2026 revenue guidance slightly above Street: management guided revenue of $264.0M–$266.0M versus consensus ~$263.2M, providing modest confirmation of continued growth. Q4 & Guidance Release
• Positive Sentiment: Analysts raised targets and reiterated buy ratings: BTIG bumped its target to $88 (buy) and Needham raised its target to $86 (buy), signaling increased analyst confidence and helping demand for the shares. Benzinga (BTIG & Needham coverage) TickerReport (Needham)
• Positive Sentiment: Company targets at least 25% revenue growth in 2026 and is expanding its minimally invasive platforms — a multi-year growth narrative that supports higher revenue expectations. MSN Article
• Neutral Sentiment: Leadership transition announced to support the next growth phase — management framed this as strategic for scale, but transitions can create short-term execution risk. Leadership Transition
• Neutral Sentiment: Full earnings call transcript is available for detail on margin trajectory, modality adoption and unit economics; useful for investors who want to dig into guidance assumptions. Earnings Call Transcript
• Negative Sentiment: Company remains unprofitable with negative net margin and a large negative ROE, meaning profitability and margin expansion are still key execution risks that could cap upside if not achieved. Zacks Coverage

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.